98 related articles for article (PubMed ID: 17012701)
1. Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis.
Block JJ
Am J Psychiatry; 2006 Oct; 163(10):1838; author reply 1838. PubMed ID: 17012701
[No Abstract] [Full Text] [Related]
2. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns.
McClellan JM
Am J Psychiatry; 2007 Oct; 164(10):1462-4. PubMed ID: 17898331
[No Abstract] [Full Text] [Related]
4. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
5. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
[TBL] [Abstract][Full Text] [Related]
6. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
7. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus placebo in the treatment of adolescents with bipolar mania.
Tohen M; Kryzhanovskaya L; Carlson G; Delbello M; Wozniak J; Kowatch R; Wagner K; Findling R; Lin D; Robertson-Plouch C; Xu W; Dittmann RW; Biederman J
Am J Psychiatry; 2007 Oct; 164(10):1547-56. PubMed ID: 17898346
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Chen CH; Huang MC; Lu ML
J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
[No Abstract] [Full Text] [Related]
11. Olanzapine and weight gain.
Isaac MB; Isaac MT
Am J Psychiatry; 2005 Sep; 162(9):1764-5; author reply 1765. PubMed ID: 16135655
[No Abstract] [Full Text] [Related]
12. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
Tohen M; Calabrese JR; Sachs GS; Banov MD; Detke HC; Risser R; Baker RW; Chou JC; Bowden CL
Am J Psychiatry; 2006 Feb; 163(2):247-56. PubMed ID: 16449478
[TBL] [Abstract][Full Text] [Related]
13. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
14. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Ascher-Svanum H; Stensland MD; Kinon BJ; Tollefson GD
J Psychopharmacol; 2005 Nov; 19(6 Suppl):110-7. PubMed ID: 16280344
[TBL] [Abstract][Full Text] [Related]
15. Methodological concerns in a trial of ziprasidone and olanzapine.
Carnahan RM; Perry PJ
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
[No Abstract] [Full Text] [Related]
16. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine treatment of eight adolescent patients with psychosis.
Ercan ES; Kutlu A; Varan A; Cikoğlu S; Coşkunol H; Bayraktar E
Hum Psychopharmacol; 2004 Jan; 19(1):53-6. PubMed ID: 14716713
[TBL] [Abstract][Full Text] [Related]
18. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
Vieweg WV; Sood AB; Pandurangi A; Silverman JJ
Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101
[TBL] [Abstract][Full Text] [Related]
19. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
[TBL] [Abstract][Full Text] [Related]
20. Safety of olanzapine.
Beasley CM; Tollefson GD; Tran PV
J Clin Psychiatry; 1997; 58 Suppl 10():13-7. PubMed ID: 9265911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
